Crohn's Disease
Crohn's Disease is an inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract from the mouth to the anus, often exhibiting patchy inflammation and affecting multiple tissue layers. Symptoms include abdominal pain, diarrhea, fever, weight loss, and complications such as anemia, skin rashes, arthritis, and an increased risk of bowel obstruction and certain cancers.
Health Outcomes
- Accelerated Colitis Recovery
- Accelerated Immune Response Maturation
- Accurate Enumeration of Viable Probiotic Bacteria
- Achieved Histological Remission
- Achieved Inflammation Homeostasis
- Activated Immune Response
- Activated Intestinal Immune Response
- Activated Systemic Immunoreactivity in Peyer's Patches
- Activation of Peyer's Patches Plasmacytoid Dendritic Cells
- Adjusted Immune Function
- Adjusted Intestinal Microbiota Abundance
- Alleviated Histopathological Changes in the Colon
- Alleviated Intestinal Damage
- Alleviated Intestinal Disease
- Alleviated Intestinal Metabolic Disorders
- Alleviated Symptoms of Mild to Moderate Crohn's Disease
- Altered Bacterial Proportions
- Altered Bifidobacterial Population
- Altered Bifidobacterium Profile
- Altered CD4+ T-cell Cytokine Levels
- Altered Chemokine Response
- Altered Colonic Microbial Communities
- Altered Cytokine Levels in Jejunal Mucosa
- Altered Dominant Intestinal Bacterial Composition
- Altered Dominant Microbial Community
- Altered Expression of Immune Products
- Altered Expression of Immune-Related Genes
- Altered Faecal Microbiota Profile
- Altered Fecal Butyrate Levels
- Altered Fecal Metabolite Levels
- Altered Gastrointestinal Microbial Communities
- Altered Gut Metabolome
- Altered Gut Microbial Community
- Altered Gut Microbial Transcriptomic Response
- Altered IFN-γ Levels
- Altered IgA Concentration in Ileal Flushes
- Altered Immune Response
- Altered Intestinal Mucosa Morphology
- Altered Intestinal Transit
- Altered Microbial Composition
- Altered Microbial Phyla Abundance
- Altered Microbial Population Composition
- Altered Microbial Profile
- Altered NF-kappaB Signaling
- Altered Pro-Inflammatory Cytokine Levels
- Altered Relative Abundance of Specific Bacteria
- Altered Serum IL-6 Levels
- Altered Serum Immune Protein Levels
- Altered Short-Chain Fatty Acid Production
- Altered Short-Chain Fatty Acid Production by Gut Microbiota
- Altered Spirochaetes Abundance in Pig Microbiota
- Altered Stool Microbiota Profile
- Altered Systemic Immune Response
- Altered T Cell Migratory Behavior
- Altered T Cell Subsets
- Attenuated Enterocyte Injury
- Attenuated Gut Dysbiosis
- Balanced Gut Microbiome
- Balanced Gut Microbiota
- Balanced Intestinal Microflora
- Balanced T-Cell Differentiation
- Balanced Treg/Th17 Regulation
- Baseline Intestinal Permeability
- Binding to Goblet Cell Mucus
- Changed Magnesium Level
- Changed Stool Consistency
- Changes in Health Status from Probiotic Intervention
- Changes in Inflammatory Markers
- Chronic Immune Activation
- Colonization of Fibrolytic Bacteria
- Colonization of the Intestine
- Corrected Gut Microbiota Disorders
- Counterbalanced Gut Dysbiosis
- Decreased Digestive Enzyme Activities in Ileum
- Decreased Hafnia-Obesumbacterium Genus
- Decreased Mannitol Flux
- Decreased Naïve CD45RA+ T Helper Cells
- Decreased Prevotella Copri Relative Abundance
- Decreased Roseburia faecis Relative Abundance
- Decreased TNF-α Production in Immune Cells
- Decreased TNFα Levels
- Delayed Onset of Colitis
- Developed Anemia
- Disrupted Gut Microbiota Distribution
- Disrupted Mucosal Barrier
- Diversified B-Cell Populations in the Colon
- Diversified B-cell Populations in the Lamina Propria
- Duration of Symptoms
- Elevated Bifidobacterium Levels
- Elevated Blood Cytokine Levels
- Elevated ERK Levels in Intestinal Stem Cells
- Elevated Fecal Acidic Steroid Levels
- Elevated Fecal IgA Levels
- Elevated Fecal Lactate Levels
- Elevated IL-10 Levels
- Elevated IL-22 Levels
- Elevated IgA Levels in Milk
- Elevated Ileum IL-4 Levels
- Elevated Interleukin-10 Levels
- Elevated Interleukin-12 Levels
- Elevated Interleukin-6 Levels
- Elevated Plasma Lysozyme Levels
- Elevated Serum IFN-γ Levels
- Elevated Serum IgG2 Levels
- Elevated Serum Immunoglobulin Levels
- Elevated Serum Metabolites in Response to Inflammation
- Elevated Serum TNF-α Levels
- Elevated Serum Total Ig Levels
- Elevated TNF-α Expression Level
- Elevated β-Catenin Levels in Intestinal Stem Cells
- Enhanced Adherence to Intestinal Epithelial Cells
- Enhanced Adhesion to Colon Cells
- Enhanced Adhesion to Enterocyte-like Cells
- Enhanced Adjuvanticity
- Enhanced Anti-Inflammatory Cytokine Production
- Enhanced Anti-Inflammatory Cytokine Secretion
- Enhanced Anti-inflammatory Cytokine Expression During Healing
- Enhanced Anti-inflammatory Cytokine Levels
- Enhanced Anti-inflammatory Properties
- Enhanced Anti-inflammatory Response
- Enhanced Antigen Uptake
- Enhanced Beneficial Bacteria in Intestinal Microbiota
- Enhanced Beneficial Gut Microbiota
- Enhanced Beneficial Metabolite Production
- Enhanced Beneficial Microbial Populations
- Enhanced Bifidobacterial Diversity
- Enhanced Bifidobacterial Growth
- Enhanced Cell-Mediated Immunity
- Enhanced Colon Bacterial Diversity
- Enhanced Colonic Mucosa Adhesion
- Enhanced Colorectal Homeostasis
- Enhanced Complement Pathway Activity
- Enhanced Cytokine Production
- Enhanced Delayed-Type Hypersensitivity Response
- Enhanced Dendritic Cell Recruitment in Intestinal Villi
- Enhanced Dendritic Cell-T Cell Interaction
- Enhanced Differentiation of Intestinal Stem Cells into Goblet Cells
- Enhanced Diversity of Protective Bifidobacterial Populations
- Enhanced Functional Gene Presence in Small Intestine
- Enhanced GLP-2 Secretion
- Enhanced Gas Passing
- Enhanced Gastrointestinal Stress Resistance
- Enhanced Gastrointestinal Survival
- Enhanced Goblet Cell Regeneration
- Enhanced Growth Performance
- Enhanced Growth of Beneficial Gut Bacteria
- Enhanced Gut Flora Composition
- Enhanced Gut Health
- Enhanced Gut Microbiome Health
- Enhanced Gut Microbiota
- Enhanced Gut Microbiota Diversity
- Enhanced Gut Microbiota Maturation
- Enhanced Gut Probiotic Bacteria Propagation
- Enhanced Gut Probiotic Levels
- Enhanced Host-Microbe Balance
- Enhanced IL-12 Production
- Enhanced Immune Cell Activity
- Enhanced Immune Function Post-Cessation
- Enhanced Immune Modulation
- Enhanced Immune Regulation
- Enhanced Immune Response
- Enhanced Immune Signaling Molecule Production
- Enhanced Immunogenicity
- Enhanced Immunomodulation
- Enhanced Immunomodulatory Function
- Enhanced Immunoregulatory Function
- Enhanced Immunoregulatory Molecule Activity
- Enhanced Inflammation Resolution
- Enhanced Inflammatory Response
- Enhanced Innate Immune Response
- Enhanced Interferon Gamma Production
- Enhanced Interleukin-10 Production
- Enhanced Intestinal Barrier Function
- Enhanced Intestinal Cell Adhesion
- Enhanced Intestinal Defense Maturation
- Enhanced Intestinal Development
- Enhanced Intestinal Epithelial Cell Adhesion
- Enhanced Intestinal Epithelial Cell Growth
- Enhanced Intestinal Epithelial Maturation
- Enhanced Intestinal Immunity
- Enhanced Intestinal Innate Mucosal Immunity
- Enhanced Intestinal Integrity
- Enhanced Intestinal MUC2 Secretion
- Enhanced Intestinal Microbiota Maturation
- Enhanced Intestinal Morphometry
- Enhanced Intestinal Mucin Production
- Enhanced Intestinal Mucosal Cell Protection
- Enhanced Intestinal Repair Processes
- Enhanced Jejunal Immune Response
- Enhanced Leukocyte Recruitment
- Enhanced Lymphocyte Proliferation
- Enhanced Metabolism in Small Intestine Microbiota
- Enhanced Mitochondrial Fitness of Intestinal Regulatory T-cells
- Enhanced Mucosal Immune Response
- Enhanced Negative Regulation of TLR Activity
- Enhanced Nutrient Bioavailability
- Enhanced Phenotypic Maturation of Dendritic Cells
- Enhanced Prebiotic Activity
- Enhanced Pro-Inflammatory Cytokine Response
- Enhanced Probiotic Activity
- Enhanced Probiotic Bacteria Count
- Enhanced Probiotic Growth
- Enhanced Regulatory T Cell Development
- Enhanced Regulatory T Cell Function
- Enhanced Regulatory T-Cells in Mesenteric Lymphoid Nodes
- Enhanced SCFA Production
- Enhanced Serum Metabolite Levels Against Inflammation
- Enhanced Small Intestine Metabolic Function
- Enhanced Specific IgG Response
- Enhanced Spleen Cell Proliferative Response
- Enhanced Suppressive Function of Intestinal Tregs
- Enhanced Survival under Gastrointestinal Stress
- Enhanced T Cell Activation
- Enhanced Tight Junction Integrity
- Enhanced Treg Cell Differentiation
- Enhanced Type 1 Immune Response
- Gastrointestinal Tract Persistence
- Germination of Probiotics in Small Intestine
- Good Tolerance to Lactobacillus Reuteri
- Gut Localization of Lactobacillus brevis
- Healed Colitis
- Healthy Gut Microbiome
- High Viability of Probiotic Lactobacillus crispatus BC4 in Cheese
- Immune Response to Rotavirus Vaccine Antigen
- Impaired Intestinal Barrier Function
- Improved Abdominal Pain
- Improved Abdominal Pain Frequency
- Improved Abdominal Pain Severity
- Improved Abdominal Pain in Colitis Patients
- Improved Absorption of Essential Trace Elements
- Improved Abundance of Beneficial Bacteria
- Improved Adherence to Enterocytes
- Improved Alpha Diversity of Intestinal Microbiota
- Improved Amino Acid Absorption
- Improved Antigen-Specific IgA Secretion
- Improved Antioxidant and Anti-Inflammatory Response
- Improved Beneficial Intestinal Microbiota
- Improved Bifidobacteria Levels
- Improved Bifidobacterium-Dominated Microbiota
- Improved Bifidogenic Response
- Improved Bioavailability
- Improved Bloating
- Improved Bowel Function
- Improved Bowel Habit Satisfaction
- Improved Bowel Habits
- Improved Bowel Movement Frequency
- Improved Bowel Movements
- Improved Bristol Stool Type
- Improved CD4- CD8+ low T Cell Percentage in Ileum
- Improved Calcium Absorption
- Improved Cell-mediated Immunity
- Improved Cellular Immune Response
- Improved Chronic Constipation
- Improved Clinical Disease Activity
- Improved Colitis
- Improved Colitis Survival
- Improved Colitis Symptoms
- Improved Colon Pain
- Improved Colonic Antioxidant Levels
- Improved Colonic Delivery
- Improved Colonic Delivery Feasibility of Oxygen-Sensitive Probiotics
- Improved Colonic Health
- Improved Colonic Histology
- Improved Colonic Histopathology
- Improved Colonic Immune Response
- Improved Colonic Length
- Improved Colonic Microbial Diversity
- Improved Colonic Microenvironment
- Improved Colonic Mucosal Integrity
- Improved Colonization of Gastrointestinal Tract by Lactobacilli
- Improved Community Diversity of Intestinal Microbiota
- Improved Constipation Symptoms
- Improved Crohn Disease Symptom
- Improved Crypt Hyperplasia
- Improved Cytokine Levels
- Improved Cytokine Production
- Improved Degradability of Acid Detergent Fiber
- Improved Dendritic Cell Activation
- Improved Diarrhea Symptoms
- Improved Digestibility
- Improved Digestibility of Amino Acids
- Improved Digestibility of Neutral Detergent Fiber
- Improved Digestive Function
- Improved Digestive Health
- Improved Digestive Performance
- Improved Digestive Symptoms
- Improved Disease Activity Index Score
- Improved Diversity of Gut Microbiota
- Improved Effectiveness in Inflammatory Bowel Disease
- Improved Endotoxemia-related Inflammation
- Improved Enteral Nutrition
- Improved Enteral Nutrition Tolerance
- Improved Enteral Nutrition Uptake
- Improved Epithelial Barrier Function
- Improved Epithelial Barrier Integrity
- Improved Epithelial Permeability
- Improved Faecal Dry Matter
- Improved Fecal Acetate Recovery
- Improved Fecal Microbial Profile
- Improved Fecal Microbiota
- Improved Fecal Score
- Improved Fecal Short-Chain Fatty Acid Levels
- Improved Fecal Water Content
- Improved Feed Utilization
- Improved Flatus
- Improved Formula Tolerance
- Improved Functional Genes in Intestinal Microbiota
- Improved Gastrointestinal Inflammation
- Improved Gastrointestinal Microbiome Balance
- Improved Gastrointestinal Resilience
- Improved Gastrointestinal Resistance
- Improved Gastrointestinal Score
- Improved Gastrointestinal Survival
- Improved Gastrointestinal Symptom Management
- Improved Gastrointestinal Symptom Rating Scale Score
- Improved Gastrointestinal Symptom Relief
- Improved Gastrointestinal Symptom Score
- Improved Gastrointestinal Symptoms
- Improved Gastrointestinal Transit Survival
- Improved General GI Health Status
- Improved General Tolerance
- Improved Granulocyte Oxidative Burst
- Improved Gross Morphology of Intestinal Tissue
- Improved Growth of Beneficial Bacteria
- Improved Gut Adhesion
- Improved Gut Bacterial Diversity
- Improved Gut Barrier Function
- Improved Gut Barrier Morphology
- Improved Gut Dysbiosis
- Improved Gut Flora Diversity
- Improved Gut Flora Modulation
- Improved Gut Health
- Improved Gut Homeostasis
- Improved Gut Immunity
- Improved Gut Inflammation
- Improved Gut Integrity
- Improved Gut Microbial Alpha Diversity
- Improved Gut Microbial Balance
- Improved Gut Microbial Dysbiosis
- Improved Gut Microbial Persistence
- Improved Gut Microbial Population
- Improved Gut Microbial Richness
- Improved Gut Microbiome
- Improved Gut Microbiome Composition
- Improved Gut Microbiome Diversity
- Improved Gut Microbiome Function
- Improved Gut Microbiome Health
- Improved Gut Microbiome Recovery
- Improved Gut Microbiota
- Improved Gut Microbiota Balance
- Improved Gut Microbiota Composition
- Improved Gut Microbiota Composition in Small Intestine
- Improved Gut Microbiota Distribution
- Improved Gut Microbiota Diversity
- Improved Gut Microbiota Fermentation
- Improved Gut Microbiota Growth Medium Suitability
- Improved Gut Microbiota Homeostasis
- Improved Gut Microbiota Richness
- Improved Gut Microbiota Structure
- Improved Gut Microbiota-Related Pathways
- Improved Gut Microflora
- Improved Gut Morphology
- Improved Gut Mucosa Health
- Improved Gut Mucosal Histology
- Improved Gut Permeability
- Improved Gut Protection
- Improved Gut Repair
- Improved Gut Resilience
- Improved Gut Stress Resistance
- Improved Gut Tolerance
- Improved Histological Healing
- Improved Histopathological Protection
- Improved Host-Gut Microbiota Related Molecular Adaptation
- Improved Host-Probiotic Interaction
- Improved IBD Remission Maintenance
- Improved IL-10/TNF-α Ratio
- Improved IgA Production
- Improved Ileal Histomorphometry
- Improved Immune Balance
- Improved Immune Cell Chemotactic Activity
- Improved Immune Parameters
- Improved Immune Regulation
- Improved Immune Response
- Improved Immune Surveillance
- Improved Immune System Maturation
- Improved Immune Tolerance
- Improved Immune-Related Symptoms
- Improved Immunity Status
- Improved Immunoglobulin Levels
- Improved Immunoinflammatory Markers
- Improved Immunologic Barrier Function
- Improved Immunological Status of Mucosa
- Improved Immunomodulation
- Improved Inflammation Homeostasis
- Improved Inflammation Levels
- Improved Inflammatory Biomarkers
- Improved Inflammatory Marker Profile
- Improved Inflammatory Profile
- Improved Inflammatory Regulation
- Improved Inflammatory Response
- Improved Inflammatory Status
- Improved Interleukin-10 Levels
- Improved Intestinal Alkaline Phosphatase Activity
- Improved Intestinal Barrier
- Improved Intestinal Barrier Function
- Improved Intestinal Barrier Integrity
- Improved Intestinal Cell Adhesion
- Improved Intestinal Cell Integrity
- Improved Intestinal Cell Proliferation
- Improved Intestinal Cell Viability
- Improved Intestinal Crypt Survival
- Improved Intestinal Cytokine Function
- Improved Intestinal Defense
- Improved Intestinal Defense Mechanism
- Improved Intestinal Development
- Improved Intestinal Digestive Enzyme Activity
- Improved Intestinal Environment
- Improved Intestinal Epithelial Barrier
- Improved Intestinal Epithelial Barrier Function
- Improved Intestinal Epithelial Cell Function
- Improved Intestinal Epithelial Intercellular Integrity
- Improved Intestinal Epithelial Permeability
- Improved Intestinal Epithelium Recovery
- Improved Intestinal Flora
- Improved Intestinal Flora Balance
- Improved Intestinal Function
- Improved Intestinal Health
- Improved Intestinal Health from Zinc Deficiency Prevention
- Improved Intestinal Histology
- Improved Intestinal Histomorphology
- Improved Intestinal Histopathology
- Improved Intestinal Immune Barrier
- Improved Intestinal Immune Response
- Improved Intestinal Immune Responsiveness
- Improved Intestinal Immunity
- Improved Intestinal Immunomodulatory Function
- Improved Intestinal Injury
- Improved Intestinal Innate Immunity
- Improved Intestinal Integrity
- Improved Intestinal LAB Viability
- Improved Intestinal Metabolism
- Improved Intestinal Microbial Composition
- Improved Intestinal Microbiota
- Improved Intestinal Microbiota Balance
- Improved Intestinal Microbiota Health
- Improved Intestinal Microenvironment
- Improved Intestinal Microflora
- Improved Intestinal Morphology
- Improved Intestinal Morphometry
- Improved Intestinal Mucosa Architecture
- Improved Intestinal Mucosal Health
- Improved Intestinal Mucosal Histology
- Improved Intestinal Mucosal Immunity
- Improved Intestinal Mucosal Repair
- Improved Intestinal Resistance to Salmonella Typhimurium
- Improved Intestinal Structure
- Improved Intestinal Survival
- Improved Intestinal Villi Epithelium Integrity
- Improved Intestinal Villus Height
- Improved Intestinal Villus Morphology
- Improved Iron Absorption
- Improved Iron Deficiency Anemia Treatment Efficacy
- Improved Iron Levels
- Improved Iron Status
- Improved Irritable Bowel Syndrome Symptoms
- Improved Jejunal Health
- Improved Jejunal Morphology
- Improved Jejunal Permeability
- Improved Macroscopic Colonic Damage
- Improved Magnesium Bioaccessibility
- Improved Malnutrition Status
- Improved Management of Colitis
- Improved Microbial Community Composition
- Improved Microbial Diversity
- Improved Microbial Metabolism Regulation
- Improved Microbiota Activity
- Improved Microbiota Diversity
- Improved Microbiota Profile
- Improved Microflora Composition
- Improved Micronutrient Availability
- Improved Micronutrient Status
- Improved Mineral Absorption
- Improved Monocyte Activation
- Improved Mucosal Barrier Function
- Improved Mucosal Healing
- Improved Niche Colonization
- Improved Nutrient Absorption and Metabolism
- Improved Oral Tolerance
- Improved Overall IBS Symptoms
- Improved Palatability and Textural Quality
- Improved Peripheral Blood Lymphocyte Proliferation
- Improved Physician Global Assessment
- Improved Prebiotic Index
- Improved Probiotic Functionality for Functional Foods Development
- Improved Probiotic Product Stability
- Improved Proliferative Capacity of Intestinal Cells
- Improved Protein Absorption
- Improved Protein Digestion
- Improved Recovery From Colitis
- Improved Recovery of Intestinal Flora
- Improved Regulatory T Cell Function
- Improved Remission
- Improved Remission Rate
- Improved Responder Rate
- Improved Response to Prebiotics
- Improved Safety and Tolerability of Probiotic Consumption
- Improved Salmonella Clearance
- Improved Serum Protein Status
- Improved Short-Chain Fatty Acid Production
- Improved Short-Chain Fatty Acids Levels
- Improved Spleen T-Cell Function
- Improved Spontaneous Bowel Movements
- Improved Stability of Gut Microbiota
- Improved Starch Degradation Potential
- Improved Starch Digestibility
- Improved Stool Characteristics
- Improved Stool Formation
- Improved Stool Frequency
- Improved Stool Quality
- Improved Strain-Level Competitive Fitness
- Improved Supplement Tolerance
- Improved Survival Rate After E. coli Challenge
- Improved Symptoms of Chronic Condition
- Improved Systemic Immune Response
- Improved T-Cell Cytokine Production
- Improved Tight Junction Protein Localization
- Improved Tissue Pathology
- Improved Tolerance to Intestinal Conditions
- Improved Tolerance to Lactobacillus rhamnosus PRSF-L477
- Improved Tolerance to Saccharomyces cerevisiae
- Improved Treatment Efficacy
- Improved Treg/Th-17 Balance
- Improved Villus Height in Duodenum
- Improved Vitamin A Content
- Improved Water Absorption
- Improved Zinc Absorption
- Increase in Beneficial Bifidobacterial Species
- Increased Abundance of Beneficial Gut Genera
- Increased Abundance of Beneficial Microbes
- Increased Abundance of Beneficial Microorganisms
- Increased Abundance of Beneficial SCFAs-Producing Bacteria
- Increased Abundance of Bifidobacterium
- Increased Abundance of Goblet Cells
- Increased Abundance of Peptostreptococcaceae
- Increased Acetic Acid Levels in Feces
- Increased Activation of Intestinal Stem Cells
- Increased Activation of Regulatory T Cells
- Increased Adhesion to Enterocytes
- Increased Adhesion to Epithelia
- Increased Alpha Diversity of Jejunal Mucosa-Associated Microbiota
- Increased Anti-Inflammatory Bacteria Abundance
- Increased Anti-Inflammatory Cytokine IL-10
- Increased Anti-Inflammatory Cytokine IL-6 Production
- Increased Anti-Inflammatory Cytokine Levels
- Increased Anti-Inflammatory Cytokines in the Small Intestine
- Increased Anti-Inflammatory Immune Cell Populations
- Increased Anti-Inflammatory Levels
- Increased Anti-inflammatory Cytokines
- Increased Anti-inflammatory to Pro-inflammatory Cytokine Ratio
- Increased Antibody Production
- Increased Antigen-Presenting Cell Activation
- Increased Apoptosis of OVA-specific TCR Tg T Cells
- Increased Autophagy in Intestinal Epithelial Cells
- Increased Bacterial Translocation
- Increased Bacteroides Levels in the Intestine
- Increased Beneficial Bacterial Species
- Increased Beneficial Bifidobacteria
- Increased Beneficial Gut Lactic Acid Bacteria
- Increased Beneficial Gut Microbiota
- Increased Beneficial Indole Derivative Production
- Increased Beneficial Intestinal Microorganisms
- Increased Beneficial Organic Acid Levels
- Increased Bifidobacteria Count
- Increased Bifidobacteria Levels in Intestine
- Increased Bifidobacteriaceae Abundance
- Increased Bifidobacterial Counts
- Increased Bifidobacterium Breve Count in Stool
- Increased Bifidobacterium Dominance in Faecal Microbiota
- Increased Bifidobacterium Levels in Feces
- Increased Bifidobacterium lactis GCL2505 Intestinal Proliferation
- Increased Bifidobacterium lactis Proliferation in the Intestine
- Increased Bifidobacterium longum Relative Abundance
- Increased Bifidobacterium-Dominated Gut Microbiota
- Increased Bloating
- Increased Bowel Movement Frequency
- Increased Bowel Movements
- Increased Bowel Mucosal Mass
- Increased Branched Chain Fatty Acids in Colonic Digesta
- Increased Butyrate Concentration
- Increased Butyrate Concentrations in Colonic Digesta
- Increased Butyrate Production
- Increased Butyrate-Producing Gut Bacteria
- Increased Butyric Acid Levels
- Increased Butyric Acid Production
- Increased CCL-20 Levels
- Increased CD103+ Dendritic Cell Count
- Increased CD3d Expression in Colon During Weaning
- Increased CD4(-)CD8(+low) T Cell Count in Ileum
- Increased CD4-Positive T-Lymphocytes in Ileal Epithelium
- Increased CD68+ Macrophage Density
- Increased CD8 Percentage
- Increased Cellulolytic Bacterial Count
- Increased Colitis Severity
- Increased Colon Barrier Biomarkers
- Increased Colon Inflammation
- Increased Colonic Butyric Acid Concentrations
- Increased Colonic Mucosa Adhesion
- Increased Colonization by Beneficial Bacteria (Bifidobacterium animalis subsp. lactis BB-12)
- Increased Colonization of S. thermophilus
- Increased Commensal Lactobacilli Levels
- Increased Complement C3 Level
- Increased Cytokine Production
- Increased Cytokine Production in Peripheral Blood Mononuclear Cells
- Increased Cytokine Response
- Increased Cytokine Secretion
- Increased Deconjugated Bile Acid Level
- Increased Defecation Frequency
- Increased Dendritic Cell Activation
- Increased Diamine Oxidase Secretion
- Increased Digestive Problem
- Increased Duodenal Inflammation
- Increased Epithelial Proliferation in the Small Intestine
- Increased Erythromycin-Resistant Enterobacterales Abundance in the Ileum
- Increased Expression of Human Beta Defensin-2
- Increased Faecal Carboxylic Acid Concentration
- Increased Fecal Acetate Levels
- Increased Fecal Acetic Acid Concentration
- Increased Fecal Bifidobacteria Numbers
- Increased Fecal Bifidobacterium Count
- Increased Fecal Bile Acid Levels
- Increased Fecal Butyric Acid Concentration
- Increased Fecal Calprotectin Levels
- Increased Fecal Cell Persistence
- Increased Fecal Concentration of Propionic Acid
- Increased Fecal Excretion
- Increased Fecal IgA Concentration
- Increased Fecal Immunoglobulin A Concentrations
- Increased Fecal Immunoglobulin A Levels
- Increased Fecal Immunological Biomarkers
- Increased Fecal Lactate Concentration
- Increased Fecal Lactate Levels
- Increased Fecal Lactic Acid
- Increased Fecal Lactic Acid Bacteria Counts
- Increased Fecal Moisture
- Increased Fecal Moisture Content
- Increased Fecal Output
- Increased Fecal Propionic Acid Levels
- Increased Fecal Secretory IgA Levels
- Increased Fecal Water Content
- Increased Fiber Carbohydrate Degradation Rate
- Increased Foxp3 Protein Levels
- Increased Frequency of Complete Spontaneous Bowel Movements
- Increased Functional Gene Abundance in Small Intestine
- Increased Functional Genes in Caeca
- Increased GLP-2 Release
- Increased GSH/GSSG Ratio
- Increased Gastrointestinal Discomfort
- Increased Genetic Diversity of Lactic Acid Bacteria Population
- Increased Gut Beneficial Microbes
- Increased Gut Lactic Acid Bacteria Count
- Increased Gut Lactobacillus plantarum Population
- Increased Gut Levels of Lactobacillus and Lactococcus
- Increased Gut Microbial Growth
- Increased Gut Microbial Supplementation
- Increased Gut Microbiota Dissimilarity
- Increased Helper T Cell Activation
- Increased IFN-gamma Secretion from Naïve T Cells
- Increased IFN-γ Levels
- Increased IFN-γ to IL-4 Ratio
- Increased IL-10 Concentration
- Increased IL-10 Levels
- Increased IL-10 Production
- Increased IL-10 in Mucosal Tissue
- Increased IL-10/TNF-α Ratio in Intestinal Fluids
- Increased IL-12 Levels
- Increased IL-12 Production
- Increased IL-12 Production in Splenocytes
- Increased IL-17 Levels
- Increased IL-2 Secretion
- Increased IL-6 Levels in Early Phase
- Increased IPA Levels
- Increased IgA Production
- Increased IgA Production by PPs
- Increased IgA-Inducing Activity
- Increased IgA-Secreting Lymphocytes in the Mucosa
- Increased Ileal Enterobacteriaceae Counts
- Increased Ileal Goblet Cell Count
- Increased Ileal Mucosal Colonization of Lactobacillus amylovorus
- Increased Ileum Interleukin-10 Levels
- Increased Ileum Length
- Increased Immune Activation without Cytotoxicity
- Increased Immune Cell Presence
- Increased Immune Marker Activation
- Increased Immune Marker Levels
- Increased Immune System Activation
- Increased Immunoglobulin A (IgA) Production
- Increased Immunoglobulin A (IgA)-Positive Cells
- Increased Immunoglobulin A+ Cells in Small Intestine
- Increased Immunoglobulin G2 Levels
- Increased Immunosuppressive Cytokine Production
- Increased Indigenous Bifidobacterium Levels
- Increased Inflammatory Cell Counts
- Increased Inflammatory Cytokines
- Increased Inflammatory Mediator Production
- Increased Inflammatory Response
- Increased Interest in Probiotic Supplements
- Increased Interferon-Gamma Levels
- Increased Interleukin 12 Secretion from Dendritic Cells
- Increased Interleukin-10 Levels
- Increased Interleukin-10 Production
- Increased Interleukin-10 Production in the Gut
- Increased Interleukin-12 Production
- Increased Interleukin-12p40 Production
- Increased Interleukin-6 Production in Macrophages
- Increased Interleukin-8 Expression in the Ileum
- Increased Intestinal Anti-E. coli IgA Levels
- Increased Intestinal Barrier Cytoprotection
- Increased Intestinal Bifidobacteria Levels
- Increased Intestinal Bifidobacteria Population
- Increased Intestinal Cell Adhesion
- Increased Intestinal Crypt Survival
- Increased Intestinal Epithelial Cell Adhesion
- Increased Intestinal IFN-beta Levels
- Increased Intestinal IgA Levels
- Increased Intestinal IgA Secretion
- Increased Intestinal Immunoglobulin A Levels
- Increased Intestinal Inflammatory Response
- Increased Intestinal Lactic Acid Bacteria Count
- Increased Intestinal Lactobacillus sakei Levels
- Increased Intestinal Motility
- Increased Intestinal Mucosal Immune Response
- Increased Intestinal Neutrophil Levels
- Increased Intestinal Permeability Under Exercise-induced Stress
- Increased Intestinal Retention Safety
- Increased Intestinal Subepidermal CD4+ Cell Levels
- Increased Intestinal T-Cell Count
- Increased Intestinal Transit Rate
- Increased Intraepithelial CD8+ Lymphocytes
- Increased Intraepithelial Leukocyte Levels
- Increased Intrinsic Bifidobacteria Levels
- Increased Jejunal Permeability
- Increased Lacticaseibacillus Abundance
- Increased Lactobacilaceae Levels
- Increased Lactobacilli Colonization in the Gut
- Increased Levels of Actinobacteria
- Increased Levels of Autochthonous Intestinal Bacteria
- Increased Levels of Indole-3-Lactic Acid
- Increased Lymphocyte Proliferation
- Increased Lymphoid Cell Proliferation in Germ-Free Animals
- Increased MUC-2 Levels
- Increased Magnesium Absorption
- Increased Mast Cells in Mucosal Tissues
- Increased Metabolic Activity in the Colon
- Increased Microbial Diversity
- Increased Microbial Richness in the Large Intestine
- Increased Microbial Viability in Human Gut
- Increased Mucosal Anti-Inflammatory Mediator MIF Production
- Increased Natural Killer Cell Frequency
- Increased Oxalate-Degrading Activity
- Increased Paneth Cell Number in Intestinal Crypts
- Increased Persistence of Beneficial Bacterial Species
- Increased Persistence of Bifidobacteria
- Increased Plasma Immunoglobulin Levels
- Increased Plasma Serotonin Levels
- Increased Population of Clostridium Histolyticum
- Increased Preference for SCFP-Containing Diet
- Increased Prevalence of Normally Formed Stools
- Increased Prevotella Concentration
- Increased Pro-inflammatory Cytokine IL-6
- Increased Pro-inflammatory Cytokine Release
- Increased Pro-inflammatory Cytokine TNFα Levels
- Increased Pro-inflammatory Cytokines in Early Healing Phase
- Increased Probiotic Bacterial Survival Through Upper Gastrointestinal Transit
- Increased Probiotic Co-existence
- Increased Probiotic Potential
- Increased Production of Anti-inflammatory Cytokine IL-10
- Increased Proportion of Activated T Lymphocytes
- Increased Proportion of Aerobic and Anaerobic Bacteria
- Increased Proportion of Intestinal Goblet Cells
- Increased Proportion of Intestinal Regulatory T Cells
- Increased Proportion of Verrucomicrobia in Gastrointestinal Microbiome
- Increased Protective Fecal Bifidobacteria
- Increased Protective Fecal Bifidobacterial Diversity
- Increased Protein Digestibility
- Increased Protozoa Counts
- Increased Regulatory T Cell Expansion
- Increased Regulatory T Cell Populations
- Increased Regulatory T Cell Response
- Increased Regulatory T Cells in Intestinal Mucosa
- Increased Regulatory T-Cells in Mesenteric Lymphoid Nodes
- Increased Relative Abundance of Beneficial Bacteria
- Increased Resistance to Simulated Gastrointestinal Conditions
- Increased Rikenellaceae Abundance
- Increased SCFA Production
- Increased SCFA-Producing Bacteria
- Increased Sarcina Levels
- Increased Secretory IgA Level
- Increased Secretory Immunoglobulin A
- Increased Serum Anti-inflammatory Metabolites
- Increased Serum Complement 3 (C3) Levels
- Increased Serum IL-10 Levels
- Increased Serum IgA Levels
- Increased Serum IgG2 Levels
- Increased Serum Lysozyme Activity
- Increased Serum Metabolites to Combat Inflammation
- Increased Serum Tumor Necrosis Factor-α Levels
- Increased Short-Chain Fatty Acid Levels
- Increased Short-Chain Fatty Acid Production
- Increased Short-Chain Fatty Acid-Producing Bacteria
- Increased Specific Antibody Production
- Increased Specific IgG Levels
- Increased Stool Consistency
- Increased Stool Frequency
- Increased Stool IgA Levels
- Increased Stool Looseness
- Increased Stool Moisture Content
- Increased Stool Volume
- Increased Susceptibility to Salmonella Infection
- Increased T Cell Activation
- Increased T-helper Type 1 Cytokine Concentrations
- Increased TNF-alpha Levels in Macrophages
- Increased TNF-α Production
- Increased Th1-Associated Cytokine Release
- Increased Th17 Polarization
- Increased Tight Junction Protein Levels
- Increased Tolerance to Gastrointestinal Conditions
- Increased Tolerance to Inflammatory Stimuli
- Increased Tolerogenic Dendritic Cells in the Intestine
- Increased Total Fecal Carboxylic Acids
- Increased Total Fecal SCFAs
- Increased Total Immunoglobulin A (IgA) Levels
- Increased Treg Population in the Small Intestine
- Increased Tumor Necrosis Factor-Alpha Levels
- Increased Tumor Necrosis Factor-Alpha Production by Dendritic Cells
- Increased Valeric Acid Levels
- Increased Vasoactive Intestinal Peptide Levels
- Increased Weight Loss
- Increased ZO-1 Production in Ileal Tissues
- Induced Immunomodulatory Effects
- Induced Th1 Cytokines
- Induction of Th1 Immune Response
- Inflammatory Disease Protection
- Influenced Systemic Immune Response
- Inhibited Autoimmune Activation
- Inhibited Changes in Short-Chain Fatty Acids
- Inhibited IκBα Degradation
- Lack of Long-Term Colonization of Bifidobacteria Strains
- Lack of Protection of Intestinal Morphology Against DON
- Lack of Sustainable Colonization
- Long-Lasting Immunomodulatory Effects After Weaning
- Maintained Colonic Epithelial Barrier Integrity
- Maintained Colorectal Homeostasis
- Maintained Crypt Length
- Maintained Digestive Function
- Maintained Fecal Short Chain Fatty Acid Levels
- Maintained Gastrointestinal Health
- Maintained Gastrointestinal Microbiome Stability
- Maintained Growth Curve
- Maintained Gut Health
- Maintained Gut Homeostasis
- Maintained Gut Microbiome Composition
- Maintained Gut Microbiome Homeostasis
- Maintained Gut Microbiota Diversity
- Maintained Gut Microbiota Stability
- Maintained Gut Permeability
- Maintained Healthy Gut Environment
- Maintained Intestinal Barrier Function
- Maintained Intestinal Barrier Integrity
- Maintained Intestinal Epithelial Homeostasis
- Maintained Intestinal Immune Tolerance
- Maintained Intestinal Microbial Abundance
- Maintained Intestinal Microbiota Balance
- Maintained Intestinal Microbiota Stability
- Maintained Intestinal Villi Integrity
- Maintained Microbiota Equilibrium
- Maintained Mucosa-Associated Immunity
- Maintained Mucosal Barrier Integrity
- Maintained Mucus Barrier Integrity
- Maintained Normal Mucosal Barrier Function
- Maintained Nutritional Quality
- Maintained Small Intestinal Permeability
- Maintained Total Protein Levels
- Maintenance of Normal Intestinal Function
- Maintenance of Stable Gut Microbiota Profile
- Maintenance of Therapeutic Probiotic Levels
- Managed Gut Microbiota Disturbance
- Mature Gut Microbiota
- Matured Antigen-Presenting Cells
- Microbial Community Characterization
- Microbial Group Modulation with Bifidobacterial Reduction
- Microbiome Biomarker of Treatment Response
- Microbiome Remodeling
- Mitigated Microbiota Changes
- Moderate Changes in Gastrointestinal Bacterial Groups
- Modification of Gastrointestinal Microbiome
- Modified Dominant Intestinal Bacterial Taxa
- Modulated Bile Acid Profile in Ileum
- Modulated Colonic Microbiota
- Modulated Cytokine Levels
- Modulated Dendritic Cell Function
- Modulated Diurnal Short-Chain Fatty Acid Production
- Modulated Eicosanoid Levels
- Modulated Gastrointestinal Hormone Levels
- Modulated Gastrointestinal Microbiota
- Modulated Gut Microbial Diversity
- Modulated Gut Microbiome Composition
- Modulated Gut Microbiota
- Modulated Host Immune Response
- Modulated Host Response
- Modulated Humoral Inflammation
- Modulated IL-18-Related Immune Response
- Modulated Immune Function in Offspring
- Modulated Immune Markers
- Modulated Immune Response
- Modulated Immune System
- Modulated Immune Tolerance
- Modulated Immunoinflammatory Parameters
- Modulated Immunologic Response
- Modulated Inflammation and Coagulation Interaction
- Modulated Inflammatory Cytokine Levels
- Modulated Inflammatory Response
- Modulated Innate Immune Response
- Modulated Intestinal Metabolite Profile
- Modulated Intestinal Microbial Community
- Modulated Intestinal Microbial Taxa
- Modulated Intestinal Microflora Composition
- Modulated Lymphocyte Populations
- Modulated Peripheral Immune Response
- Modulated Systemic Immune Response
- Modulation of Colon Epithelium by Lactate
- Modulation of Microbiota Activity
- Neutral Probiotic Delivery Through Digestion
- No Change in C-Reactive Protein
- No Change in Colitis-Induced Inflammation
- No Change in Endogenous Bifidobacteria Species
- No Change in Faecal Butyrate Concentration
- No Change in Fecal Abundance of L34 or LGG
- No Change in Fecal Metabolome
- No Change in Fecal Short-Chain Fatty Acid Concentration
- No Change in Gastrointestinal Survival
- No Change in Inflammatory Cytokines
- No Change in Intestinal Mucosa Morphology
- No Change in Nutrient Digestibility or Blood/Immune Markers
- No Demonstrated Efficacy for Isolated Bifidobacterium Use
- No Improvement in Gastrointestinal Permeability
- No Improvement in Growth Performance
- No Increase in Fecal Incontinence
- No Meaningful Change in IL-10
- No Meaningful Change in IL-8
- No Protection Against Salmonella-Induced Inflammation
- No Significant Acute Effect on Calcium Metabolism
- No Significant Change in Duration of Gastrointestinal Symptoms
- No Significant Change in Tumor Necrosis Factor Alpha Levels
- No Significant Effect on Anxiety Levels
- No Significant Effect on C-Reactive Protein Levels
- No Worsening of Gastrointestinal Symptoms
- Non-Toxicity to Normal Colon Cells
- Normalized Gut Metabolites
- Normalized Gut Microbiota
- Normalized Osmotic Pressure in the Large Intestine
- Normalized Serum IL-10 Levels
- Normalized Stool Consistency
- Normalized Stool Type
- Partial Restoration of Intestinal Cell Proliferation
- Partial Restoration of Intestinal Microbiota
- Potential Probiotic Benefits
- Presence of Enterocyte Vacuoles
- Preserved Colon Goblet Cell Density
- Preserved Endogenous Bifidobacteria Composition
- Preserved Gastrointestinal Histological Structure
- Preserved Gut Microbiota Diversity
- Preserved Mucosal Epithelia
- Preserved Small Intestinal Villus Integrity
- Prevention and Treatment of Inflammatory Diseases
- Prevention of Autoimmune Disorders
- Prevention of Colitis
- Prevention of Colorectal Cancer
- Prevention of Inflammatory Bowel Disease Characteristics
- Prevention of Intestinal Barrier Damage
- Prevention of Weight Loss
- Promoted Recovery from Colitis-Associated Dysbiosis
- Promotion of Healthy Gut Microbial Colonization
- Protected Enterocyte Structure
- Protected Epithelial Cells Under Inflammatory Conditions
- Protected Intestinal Health
- Protected Small Intestinal Integrity
- Protection Against Brush Border Damage Induced by Bacteria
- Protection Against Colitis
- Protection Against Gut Tissue Damage
- Protection Against Intestinal Epithelial Injury
- Rapid Galactooligosaccharide Degradation During Gastrointestinal Transit
- Rebalanced Th1/Th2/Th17 Cell Ratios
- Recovered Colon Length
- Recovered Microbiome-associated Dysbiosis
- Reduced AQP8 Expression in Colon
- Reduced Abdominal Cramping
- Reduced Abdominal Discomfort
- Reduced Abdominal Distension
- Reduced Abdominal Dysfunction
- Reduced Abdominal Pain
- Reduced Abdominal Pain Frequency
- Reduced Abdominal Pain Intensity
- Reduced Abdominal Pain Severity
- Reduced Abdominal Surgery Incidence
- Reduced Abdominal Symptoms
- Reduced Abundance of Enterobacteriaceae Species
- Reduced Abundance of Odoribacter
- Reduced Abundance of Pathobionts
- Reduced Abundance of Pro-inflammatory Bacteria
- Reduced Abundance of Streptococcus Bacteroides Enterococcus Veillonella
- Reduced Acetate Production
- Reduced Adherence of Campylobacter jejuni to Intestinal Cells
- Reduced Adipose Tissue Wasting
- Reduced Aggravation of Chronic Inflammation
- Reduced Anti-Enterococcus faecalis IgG Levels
- Reduced Antinutrient Levels
- Reduced Apoptosis of Jejunal Mucosal Cells
- Reduced B Cell Count in Draining Lymph Nodes
- Reduced Bacterial Translocation
- Reduced Bacterial Translocation in Mesenteric Adipose Tissue
- Reduced Bacterial Translocation to Mesenteric Lymph Nodes
- Reduced Bacteroides Abundance
- Reduced Bacteroides Fragilis Group Numbers
- Reduced Beta-Glucuronidase Activity
- Reduced Bifidobacterial Population
- Reduced Bifidobacterium Counts
- Reduced Bifidobacterium longum
- Reduced Bile Acid Reabsorption
- Reduced Bitter-Related Organic Acids
- Reduced Bloating Severity
- Reduced Body Weight in TNBS Colitis
- Reduced Bowel Discomfort Symptoms
- Reduced Bowel Dysfunction
- Reduced Bowel Movements
- Reduced Butyrate Production
- Reduced C-Reactive Protein Levels
- Reduced CD4+ T Cell Lymphocytes in Intestinal Mucosa
- Reduced Campylobacter Coli Colonization
- Reduced Campylobacter jejuni Inhibition
- Reduced Campylobacter jejuni Survival
- Reduced Cellular Invasion by Enterovirulent Bacteria
- Reduced Chemokine Production
- Reduced Circulating Endotoxin
- Reduced Clinical Relapse Rates
- Reduced Clinical Symptoms of Colitis
- Reduced Clostridia Cluster XIV
- Reduced Clostridia Counts
- Reduced Clostridium Counts
- Reduced Clostridium Species Numbers
- Reduced Coliform Levels in the Jejunum
- Reduced Colitis Development
- Reduced Colitis Inflammation
- Reduced Colitis Recurrence
- Reduced Colitis Risk
- Reduced Colitis Severity
- Reduced Colitis Symptoms
- Reduced Colitis-Associated Weight Loss
- Reduced Colitis-Related Mortality
- Reduced Colon Length
- Reduced Colon Pain
- Reduced Colon Shortening
- Reduced Colonic Atrophy
- Reduced Colonic Damage
- Reduced Colonic Enterobacteriaceae Species
- Reduced Colonic Inflammation
- Reduced Colonic Microscopic Damage
- Reduced Colonic Mucosa Damage
- Reduced Colonic Myeloperoxidase Levels
- Reduced Colonic Oxidative Damage
- Reduced Colonic Pathology
- Reduced Colonic Permeability
- Reduced Colonisation of Lactobacillus casei Strain Shirota
- Reduced Colonization of Cronobacter sakazakii in Enterocytes
- Reduced Colorectal Tumorigenesis
- Reduced Constipation
- Reduced Constipation Incidence
- Reduced Constipation Prevalence
- Reduced Copper Level
- Reduced Crohn's Disease Relapse
- Reduced Crypt Cell Proliferation
- Reduced Crypt Depth
- Reduced Cyclooxygenase-2 Levels
- Reduced Cytokine Production in Colonic Epithelial Cells
- Reduced Cytotoxic T Cells in Peyer's Patches
- Reduced Days with Defecation Urgency
- Reduced Defense Gene Activity for Gram-Negative Pathogens
- Reduced Deferribacteres in Gut Microbiota
- Reduced Detection Rates of Clostridium
- Reduced Diarrhea Episodes
- Reduced Diarrhea Frequency
- Reduced Diarrhea Severity
- Reduced Digestive Symptoms
- Reduced Disease Activity
- Reduced Disease Activity Index (DAI) Levels
- Reduced Disease Activity Index Scores
- Reduced Disease Activity Index in Colitis Model
- Reduced Disease Activity in Colitis
- Reduced Duration of Gastrointestinal Symptoms
- Reduced Dysbiosis
- Reduced Dysbiosis-Associated Bacteria Growth
- Reduced EHEC Colonization
- Reduced Effects of Inflammatory Bowel Disease
- Reduced Elevated Immune Cells in Mesenteric Lymph Nodes
- Reduced Enteritis
- Reduced Enteritis Index
- Reduced Enterobacteria Levels
- Reduced Enterobacteriaceae in Intestines
- Reduced Enterobacterial Counts
- Reduced Enterocyte Damage
- Reduced Enterocyte Injury from Capsaicin
- Reduced Enterocyte Layer Colonization by Salmonella enterica
- Reduced Enteropathy
- Reduced Epithelial Barrier Disruption
- Reduced Epithelial Permeability
- Reduced Escherichia Abundance
- Reduced Escherichia Vulneris Abundance
- Reduced Excitability of Enteric Neurons
- Reduced Expression of Caspase-1 in Ileum
- Reduced Expression of Inflammation-Related Genes
- Reduced Expression of Proinflammatory Mediators
- Reduced FITC-Dextran Flux Upregulation
- Reduced Faecal Calprotectin
- Reduced Faecal Levels of Total Lactobacillus Species
- Reduced Faecal pH
- Reduced Fecal Acetate
- Reduced Fecal Bacterial Enzyme Activity
- Reduced Fecal Bacterial Nitroreductase Activity
- Reduced Fecal Calprotectin Immunoglobulin A
- Reduced Fecal Calprotectin Levels
- Reduced Fecal Clostridium Levels
- Reduced Fecal Coliform Levels
- Reduced Fecal Enterobacilli
- Reduced Fecal Escherichia coli Levels
- Reduced Fecal Excretion of Bacteroides Fragilis
- Reduced Fecal Hydrogen Sulfide Emissions
- Reduced Fecal Immune Biomarkers
- Reduced Fecal Loading
- Reduced Fecal Metabolite Levels
- Reduced Fecal Score
- Reduced Fecal p-Cresol Levels
- Reduced Feeding Intolerance
- Reduced Fermentation Time
- Reduced Flatulence
- Reduced Flavonifractor Abundance
- Reduced Fluctuations in Intestinal Bacteria
- Reduced Fungal Enteric Colonization
- Reduced GLP-1 Receptor Positive Cells in Colon
- Reduced Gastrointestinal Adverse Events
- Reduced Gastrointestinal Discomfort Symptoms
- Reduced Gastrointestinal Disease Incidence in Children
- Reduced Gastrointestinal Disease Symptoms
- Reduced Gastrointestinal Disorder Symptoms
- Reduced Gastrointestinal Disorders
- Reduced Gastrointestinal Inflammation
- Reduced Gastrointestinal Leakage
- Reduced Gastrointestinal Symptom Rating Scale Score
- Reduced Gastrointestinal Symptom Severity
- Reduced Gastrointestinal Symptoms
- Reduced Gastrointestinal Symptoms Score
- Reduced Gastrointestinal Tract Histological Damage
- Reduced Gemmiger formicilis Abundance
- Reduced Genera Romboutsia
- Reduced Groalpha Secretion
- Reduced Gut Barrier Defect
- Reduced Gut Damage
- Reduced Gut Disorders
- Reduced Gut Humoral Proinflammatory Response
- Reduced Gut IFN-γ Production
- Reduced Gut Inflammation
- Reduced Gut Leakage
- Reduced Gut Membrane Barrier Damage
- Reduced Gut Permeability
- Reduced Gut Proteobacteria
- Reduced Hard Stool
- Reduced Harmful Gut Microbiota
- Reduced Harmful Intestinal Metabolites
- Reduced Histologic Remission
- Reduced Histopathological Damage
- Reduced Humoral Immunity to Bacteroides thetaiotaomicron
- Reduced Hyperexcitability of Colonic DRG Neurons
- Reduced IBD Symptoms
- Reduced IBS Severity
- Reduced IL-10 Expression in Ileum
- Reduced IL-12p70 Release
- Reduced IL-17 Production in Splenocytes
- Reduced IL-18 Expression in Ileum
- Reduced IL-1β Expression in Ileum
- Reduced IL-1β Levels
- Reduced IL-6 Concentration
- Reduced IL-6 Production
- Reduced IL-6 Secretion
- Reduced IL-8 Secretion
- Reduced IL6 Production in Intestinal Epithelial Cells
- Reduced IkappaB Alpha Degradation
- Reduced Ileal Malondialdehyde (MDA) Levels
- Reduced Ileal Oxidative Damage
- Reduced Ileum Inflammation
- Reduced Ileum Mucosa Damage
- Reduced Immune Activation
- Reduced Immune Cell Infiltration
- Reduced Immunogenicity After Oral Vaccination
- Reduced Immunoinflammatory Markers
- Reduced Impact on Existing Indigenous Microbiota
- Reduced Incidence of Acute Colitis
- Reduced Incidence of Chronic Diarrhea
- Reduced Incidence of Chronic Inflammatory Diseases in Smokers
- Reduced Incidence of Colon Cancer
- Reduced Incidence of Gastrointestinal Adverse Events
- Reduced Incidence of Inflammatory Bowel Diseases
- Reduced Incidence of Lactobacillus Bacteremia
- Reduced Incidence of Watery Diarrhea
- Reduced Indigenous Enterobacteria Colonization
- Reduced Inducible Nitric Oxide Synthase Expression in Intestinal Tissue
- Reduced Inflammation
- Reduced Inflammation Levels
- Reduced Inflammation Markers
- Reduced Inflammation from Salmonella Typhimurium
- Reduced Inflammation in Dendritic Cells
- Reduced Inflammation in Inflammatory Bowel Disease
- Reduced Inflammation in Intestinal Enterocytes
- Reduced Inflammation in Premature Intestinal Cells
- Reduced Inflammation via Gut Microbiota
- Reduced Inflammatory Activities
- Reduced Inflammatory Bowel Disease Symptoms
- Reduced Inflammatory Cell Activity
- Reduced Inflammatory Cytokine Secretion from Activated T Cells
- Reduced Inflammatory Cytokines (TNF-α, IFN-γ, IL-6)
- Reduced Inflammatory Diseases
- Reduced Inflammatory Effects
- Reduced Inflammatory Factor Production
- Reduced Inflammatory Immune Mediators
- Reduced Inflammatory Infiltrate
- Reduced Inflammatory Injury
- Reduced Inflammatory Marker IL-1β
- Reduced Inflammatory Marker Protein Levels
- Reduced Inflammatory Markers
- Reduced Inflammatory Markers in Crohn's Disease
- Reduced Inflammatory Mediators
- Reduced Inflammatory Molecules
- Reduced Inflammatory Parameters
- Reduced Inflammatory Pathway Activity
- Reduced Inflammatory Pathways
- Reduced Inflammatory Processes
- Reduced Inflammatory Protein Activation
- Reduced Inflammatory Response
- Reduced Inflammatory Response in Intestinal Cells
- Reduced Inflammatory Response to Inflammatory Stimulus
- Reduced Inflammatory Stimulators
- Reduced Inflammatory Tone
- Reduced Injury-Induced Gut Inflammation
- Reduced Interferon-Gamma Production
- Reduced Interleukin Level
- Reduced Interleukin-1β Concentration
- Reduced Interleukin-22 Level
- Reduced Interleukin-8 Secretion
- Reduced Intestinal Aging
- Reduced Intestinal Apoptosis
- Reduced Intestinal Cell Adhesion
- Reduced Intestinal Cell Death
- Reduced Intestinal Cholesterol Absorption
- Reduced Intestinal Damage
- Reduced Intestinal Epithelial Apoptosis
- Reduced Intestinal Fibrosis
- Reduced Intestinal Histological Damage
- Reduced Intestinal Hyperpermeability
- Reduced Intestinal Immune Cell Count
- Reduced Intestinal Immunopathology
- Reduced Intestinal Inflammation
- Reduced Intestinal Inflammation Severity
- Reduced Intestinal Lesion Scores
- Reduced Intestinal Mucosal Immune Response
- Reduced Intestinal Myeloperoxidase Level
- Reduced Intestinal NE Lesion Score
- Reduced Intestinal Oxidative Damage
- Reduced Intestinal Pathogen Prevotella
- Reduced Intestinal Pathology
- Reduced Intestinal Pathology Changes
- Reduced Intestinal Permeability
- Reduced Intestinal Permeability Defect
- Reduced Intestinal Proinflammatory Cytokine Levels
- Reduced Intestinal Salmonella Burden
- Reduced Intestinal Tissue Damage
- Reduced Intestinal Tissue Injury
- Reduced Intestinal Transit Time
- Reduced LPS Translocation
- Reduced LPS-Induced Cellular Activity
- Reduced LPS-Induced Inflammation
- Reduced Lesion Size
- Reduced Levels of Anti-Inflammatory Cytokines
- Reduced Levels of Interleukin-17
- Reduced Levels of Pro-Inflammatory Cytokines (IL-1β, IL-6, IFN-γ, TNF-α)
- Reduced Lipid Peroxidation in Colonic Mucosa
- Reduced Listeria Colonization
- Reduced Local Inflammation
- Reduced Low-Grade Inflammation
- Reduced Low-grade Intestinal Inflammation
- Reduced Lower Intestinal pH
- Reduced MPO Levels
- Reduced Macromolecule Permeability
- Reduced Metabolic Functions of Intestinal Microbiota
- Reduced Methane Metabolism
- Reduced Methanobrevibacter Levels
- Reduced Microbial Richness
- Reduced Microbial Translocation
- Reduced Morphological Damage of the Jejunum
- Reduced Mucosal Adherent Citrobacter rodentium
- Reduced Mucosal Cytokine Response
- Reduced Mucosal Damage
- Reduced Mucosal Inflammation
- Reduced Mucosal Permeability
- Reduced Mucosal Pro-Inflammatory Activity
- Reduced Mucosal Thickness
- Reduced Mycotoxin Bioavailability
- Reduced NDF Digestibility
- Reduced NF-kappaB Activation due to S. Typhimurium
- Reduced Neurally Evoked Ion Secretion in the Colon
- Reduced Neutrophil Extracellular Trap Formation
- Reduced Neutrophil Recruitment
- Reduced Nuclear Factor Kappa B Activation
- Reduced Nutrient Content
- Reduced Nutritional Status
- Reduced Occurrence of Soft Stools
- Reduced Odds of Probiotic Lactobacilli Successful Colonization
- Reduced Opportunistic Pathogens
- Reduced Oral Aphthae Symptoms
- Reduced Oral Aphthosis Frequency
- Reduced Oxalate Nephropathy
- Reduced Oxidative Stress in Ileum Mucosa
- Reduced Oxidative Stress in Intestinal Epithelial Cells
- Reduced Painful Defecation
- Reduced Pathogen Translocation to Visceral Tissues
- Reduced Pathological Characteristics of the Intestinal Tract
- Reduced Percentage of Bacteroidaceae in Gut Microbiota
- Reduced Peripheral Inflammation
- Reduced Phospho-p65 Translocation
- Reduced Plasma IL-10 Levels
- Reduced Plasma Tumor Necrosis Factor-α Levels
- Reduced Population of Fusobacterium prausnitzii
- Reduced Precursor Amino Acid Availability
- Reduced Prevalence of Iron Deficiency
- Reduced Prevalence of Proteobacteria
- Reduced Pro-Inflammatory Bacteria Levels
- Reduced Pro-Inflammatory Cells
- Reduced Pro-Inflammatory Cytokine Interleukin-15 Levels
- Reduced Pro-Inflammatory Cytokine Synthesis
- Reduced Pro-Inflammatory Cytokines
- Reduced Pro-Inflammatory Factor TNF-α
- Reduced Pro-Inflammatory Immune Activity
- Reduced Pro-Inflammatory Mediator Production
- Reduced Pro-inflammatory Cytokine Expression in Ileum
- Reduced Pro-inflammatory Cytokine Interleukin-8 Levels
- Reduced Pro-inflammatory Cytokine Levels
- Reduced Pro-inflammatory Cytokine Production in LPS-stimulated Cells
- Reduced Pro-inflammatory Cytokine Release
- Reduced Pro-inflammatory Effect
- Reduced Pro-inflammatory Gene Transcription
- Reduced Pro-inflammatory Immune Responses
- Reduced Pro-inflammatory Mediator Levels
- Reduced Proinflammatory Cytokine Production
- Reduced Proinflammatory Cytokine Secretion
- Reduced Proinflammatory Cytokines Gene Transcription
- Reduced Proinflammatory Cytokines in Middle-aged Adults
- Reduced Proinflammatory Factor Levels
- Reduced Proinflammatory Factors
- Reduced Proinflammatory Mediators
- Reduced Proinflammatory Profile
- Reduced Proinflammatory Profile from Cow Milk Formula
- Reduced Proinflammatory Signaling
- Reduced Proinflammatory/Anti-inflammatory Cytokine Ratios
- Reduced Prolonged Diarrhea
- Reduced Proportion of Fusobacteria
- Reduced Proportion of Pathogenic Genus
- Reduced Proportion of Proteobacteria
- Reduced Pseudomonas in Feces
- Reduced Radiological Damage in the Gut
- Reduced Recurrence Risk
- Reduced Red Blood Cell Folate Concentration
- Reduced Relapse Rate
- Reduced Relative Abundance of Bacteroidales
- Reduced Relative Abundance of Coriobacteriaceae
- Reduced Relative Abundance of Escherichia-Shigella
- Reduced Relative Abundance of Sutterella
- Reduced Release of Inflammatory Mediators (TNF-α, IL-6, IL-1β, IL-10)
- Reduced Richness Indicators in Ileum
- Reduced Risk of Abdominal Surgery or Death
- Reduced Risk of Chronic Inflammatory Diseases
- Reduced Risk of Low Bone Mineral Density
- Reduced Risk of Obesity
- Reduced Risk of Prolonged Diarrhea
- Reduced Ruminococcus Abundance
- Reduced S. Enteritidis Invasion
- Reduced S. Typhimurium Infection
- Reduced Salmonella Translocation
- Reduced Salmonella Typhimurium Activity
- Reduced Secretory IgA Content in Faeces
- Reduced Secretory Immunoglobulin A in Stools
- Reduced Sellimonas Abundance
- Reduced Sensitivity to Tetrodotoxin (TTx) Inhibition in Short-circuit Current Response
- Reduced Serum Anti-Lactic Acid Bacteria IgA Levels
- Reduced Serum Cytokine Levels
- Reduced Serum Diamine Oxidase Activity
- Reduced Serum Endotoxin Level
- Reduced Serum Ferritin Levels
- Reduced Serum Inflammatory Factors
- Reduced Serum LPS Levels
- Reduced Serum Somatostatin Levels
- Reduced Serum TNF-α Levels
- Reduced Serum Tumor Necrosis Factor-α
- Reduced Severe Necrotizing Enterocolitis (NEC)
- Reduced Severity of Acute Colitis
- Reduced Severity of Chemotherapy-Induced Enteropathy
- Reduced Severity of Colon Lesions
- Reduced Severity of Gastrointestinal Disorders
- Reduced Short-Chain Fatty Acid Levels in Feces
- Reduced Short-Chain Fatty Acid Levels in the Colon
- Reduced Short-Chain Fatty Acids (SCFA)
- Reduced Sitosterol Absorption
- Reduced Small Intestinal Transit Time
- Reduced Small-Intestinal Damage
- Reduced Small-Intestinal Enteropathy
- Reduced Small-intestinal Ulcers
- Reduced Steroid Load
- Reduced Steroid Usage
- Reduced Stool Consistency
- Reduced Stress-Induced Intestinal Hyperpermeability
- Reduced Sulphite-Reducing Clostridia
- Reduced Susceptibility to Inflammatory Exposure
- Reduced Swede Score
- Reduced Symptoms of Oral Aphthous Ulcers
- Reduced Systemic Inflammatory Response
- Reduced T-Effector Memory Cell Activity
- Reduced TLR Inflammatory Activation
- Reduced TNF Production
- Reduced TNF-alpha Level
- Reduced TNF-α Concentration
- Reduced TNF-α Levels
- Reduced TNF-α Levels in Mesenteric Lymph Nodes
- Reduced TNF-α Secretion
- Reduced TNF-α Signaling
- Reduced Th17/Tregs Cell-Differentiation Ratio in Mesenteric Lymph Nodes
- Reduced Threonine
- Reduced Time Spent for Defecation
- Reduced Time to First Formed Stool
- Reduced Time to Maximum Amino Acid Concentration
- Reduced Tissue Damage from Colitis
- Reduced Total Immune Cells in Draining Lymph Nodes
- Reduced Transepithelial Resistance
- Reduced Tumor Necrosis Factor Alpha
- Reduced Tumor Necrosis Factor Alpha Production
- Reduced Tumor Necrosis Factor-alpha Level
- Reduced Tumor Necrosis Factor-α (TNF-α)
- Reduced Tumor Necrosis Factor-α Levels
- Reduced Turicibacter Abundance
- Reduced Urgency of Bowel Movements
- Reduced Urinary Oxalate Excretion
- Reduced Valeric Acid Levels
- Reduced Villus Height
- Reduced Visceral Pain
- Reduced Vitamin B12 Level
- Reduced Vitamin E Level
- Reduced Weight Gain
- Reduced Weight Gain and Fat Mass
- Reduced Weight Loss in Colitis Mice
- Reduced Yersinia Pseudotuberculosis Invasion
- Reduced Zinc Level
- Reduced Zonulin Level
- Reestablished Intestinal Microecology
- Regression of Gastrointestinal Disorders
- Regulated Colonic Bacterial Flora
- Regulated Gastrointestinal Function
- Regulated Gut Microbiota
- Regulated Gut Microbiota Metabolic Function
- Regulated Host Epithelial Cells
- Regulated Immune Cell Proliferation
- Regulated Immune Response
- Regulated Inflammation
- Regulated Inflammatory Cytokines
- Regulated Inflammatory Markers
- Regulated Inflammatory Process
- Regulated Inflammatory Responses
- Regulated Intestinal Barrier Function
- Regulated Intestinal Microbiota
- Regulated Intestinal Microbiota Balance
- Regulated Intestinal Microorganisms
- Relief from Rectal Tearing or Bleeding After Bowel Movement
- Relieved Abdominal Dysfunction
- Relieved Intestinal Impairments
- Remodeled Intestinal Microbiota
- Repaired Colon Tissue
- Requirement for Sustained Dosage in Gastrointestinal Tract
- Resolved Keratomalacia
- Restored Aggregation Phenotype and Protective Effect on Colitis
- Restored Barrier Function
- Restored Colonic Water Transport
- Restored Goblet Cell Count
- Restored Gut Microbiome Balance
- Restored Gut Microbiota
- Restored Gut Microbiota Diversity
- Restored Gut Microbiota Homeostasis
- Restored Gut Microbiota Structure
- Restored Healthy Gut Microbial Balance
- Restored Immune Organ Structure
- Restored Intestinal Barrier Function
- Restored Intestinal Microbiota Balance
- Restored Intestinal Structure
- Restored Microbial Balance
- Restored Microbiome Composition
- Restored Mucin-2 Levels
- Restored Mucus Layer Integrity
- Restored Protective Effect in Colitis
- Restored Regulatory T Cell Population
- Restored Regulatory T Cell Population in Mesenteric Lymph Nodes
- Restored Relative Abundance of Specific Bacteria
- Restored Short-Chain Fatty Acid Levels
- Restored T-Cell Population
- Restored Treg Cell Population in MLNs
- Reversed Microbiome Metabolic Changes
- Reversed Toxin-Induced Inhibition of Protein Synthesis in Colonic Cells
- Safety of Bifidobacterium infantis Supplementation
- Safety of Probiotic Strain Lactobacillus rhamnosus PRSF-L477
- Safety of Probiotic Supplementation
- Stabilized Cytokine Levels
- Stabilized Fecal Dry Matter Percentage
- Stabilized Gut Microbiota
- Stabilized Intestinal Microbiota
- Stable Bowel Function
- Stable Cytokine Levels in Gut-Associated Lymphoid Tissue
- Stable Fecal Deconjugated Bile Acid Levels
- Stable Fecal pH
- Stable Immune System Responses
- Stable Inflammatory Responses
- Stable Proinflammatory Cytokine Levels
- Stable Systemic Inflammatory Response
- Stimulation of Immune Cells
- Successful Gut Colonization
- Suppressed Enterobacteriaceae Levels
- Suppressed Inflammatory Chemokine Secretion
- Suppressed TNF-α Induced Genes
- Survival Through Human Intestine
- Sustained Anti-Inflammatory Gene Transcription
- Sustained Bifidobacteria Populations
- Th1 Polarized Immune Response Through Activation of moDCs
- Tolerance to Lactobacillus rhamnosus PRSF-L477
- Transient Replacement of Native Bifidobacterium longum
- Unchanged Fecal Antibiotic Resistance
- Unchanged Fecal IgA Levels
- Unchanged Gastrointestinal Resistance
- Unchanged Gastrointestinal Symptoms
- Unchanged Gut Microbiota Diversity
- Unchanged Stool Consistency or Bowel Frequency
- Unchanged Stool Frequency
- Upregulated Macrophage Inhibitory Factor
- Worsened Autoimmune Manifestations
- Worsened Fecal Scores